Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,490.00
Bid: 12,486.00
Ask: 12,490.00
Change: 98.00 (0.79%)
Spread: 4.00 (0.032%)
Open: 12,468.00
High: 12,508.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-London stocks slip after glum GDP data, end with second week of gains

Fri, 10th Dec 2021 10:09

* AstraZeneca falls on price target cut

* UK economy barely grew in October

* Data raises doubts around rate hikes

* FTSE 100 off 0.4%, FTSE 250 down 0.9%
(Adds comments, updates prices throughout)

By Bansari Mayur Kamdar

Dec 10 (Reuters) - UK's FTSE 100 and mid caps indexes
slipped for a third straight session on Friday after data
pointed to stalling economic growth in Britain, even before the
emergence of the Omicron coronavirus variant, but ended their
second week in the black.

The benchmark FTSE 100 index eased 0.4% pressured by
the healthcare sector after heavyweight drugmaker
AstraZeneca fell 2.0% after Berenberg cut its price
target on the stock.

The main index clocked its biggest weekly gain in eight
months, boosted by a strong recovery in mining stocks.

"We're seeing a flight to safety with defensive names like
British American Tobacco on the front foot," said Justin
McQueen, market analyst at DailyFX.

"The sort of news around Omicron and the government
announcing its plan B and suggestions around plan C does put the
final nail in the coffin for a rate rise next week."

Data showed Britain's economy grew by a weaker-than-expected
0.1% in October, leaving it 0.5% smaller than it was in February
2020, just before the country went into its first COVID-19
lockdown.

"The big drop in people visiting pubs, bars and restaurants
doesn't bode well for the idea that we're all rediscovering our
freedom post-lockdown. Perhaps this catalyst has now played out
and people are yearning for the warmth of their home during the
autumn and winter instead," said Russ Mould, investment director
at AJ Bell.

The domestically focussed mid-cap index fell 0.9%,
after Ashmore Group dropped 2.7% as Goldman Sachs
downgraded the asset manager to "neutral".

The numbers further raised doubts about a December rate hike
after Prime Minister Boris Johnson this week announced new
coronavirus guidelines ordering people to work from home, wear
masks in public places and use vaccine passes for bit public
events.

Capping losses on the main index, miners
gained 0.7% tracking copper prices, and defensive stocks such as
consumer staples, which tend to be less sensitive to the
economic climate, also rose.

British American Tobacco gained nearly 2.5% after a
Wall Street Journal report that said the U.S. Senate was
dropping a proposal to impose higher taxes on vaping, oral
nicotine and other NGPs.
(Reporting by Bansari Mayur Kamdar in Bengaluru
Editing by Subhranshu Sahu, Amy Caren Daniel and Frances Kerry)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.